A Milestone for Rare Disease Treatment (Image Credits: Unsplash)
The European Commission granted marketing authorization to Crinetics Pharmaceuticals for Palsonify (paltusotine) on April 27, 2026, marking the drug’s first approval outside the United States. This decision covers all 27 EU member states plus three European Economic Area countries, offering a novel once-daily oral therapy to adults with acromegaly. The approval builds on robust phase 3 data and positions Palsonify as a potential shift from traditional injectable treatments.[1][2]
A Milestone for Rare Disease Treatment
Crinetics, based in San Diego, California, celebrated the approval as a key step in its mission to redefine endocrinology care. The company submitted its marketing authorization application to the European Medicines Agency last year, following validation in March 2025 and orphan drug designation earlier that February. The EMA’s Committee for Medicinal Products for Human Use issued a positive opinion in late February 2026, paving the way for the Commission’s final nod.[1][2]
“The European Commission’s decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this important therapy to even more people living with acromegaly,” stated Scott Struthers, Ph.D., founder and chief executive officer of Crinetics.[1] Paltusotine, a nonpeptide agonist targeting somatostatin receptor type 2, suppresses excess growth hormone and insulin-like growth factor 1, key drivers of the condition.
Understanding Acromegaly’s Burden
Acromegaly affects roughly three to four people per million annually, stemming from pituitary tumors that overproduce growth hormone. Untreated, it leads to enlarged bones, organ growth, joint pain, headaches, excessive sweating, fatigue, and heightened risks of diabetes, heart disease, and certain cancers. Surgery remains the first-line approach, but many patients require lifelong medical management due to incomplete tumor removal or inoperability.[2]
Current standards rely on monthly injectable somatostatin receptor ligands like octreotide or lanreotide, which control symptoms but often cause injection-site reactions and fluctuating drug levels. Patients frequently report disruptions from these therapies, creating demand for more convenient alternatives.
Strong Results from Pivotal Trials
Palsonify’s approval rested on data from the PATHFNDR-1 and PATHFNDR-2 phase 3 studies. In PATHFNDR-2, among treatment-naive or uncontrolled patients, 55.7 percent achieved normalized IGF-1 levels after 24 weeks, compared to 5.3 percent on placebo. PATHFNDR-1 showed 83.3 percent of patients switching from injectables maintained control at 36 weeks, versus 3.6 percent on placebo.[2][1]
| Trial | Population | Palsonify Success Rate | Placebo Rate |
|---|---|---|---|
| PATHFNDR-1 | Switching from injectables | 83.3% maintained IGF-1 control (36 weeks) | 3.6% |
| PATHFNDR-2 | Treatment-naive/uncontrolled | 55.7% normalized IGF-1 (24 weeks) | 5.3% |
Both trials demonstrated rapid effects, with most responders normalizing IGF-1 within two to four weeks. Long-term extensions confirmed sustained biochemical control and symptom relief, including reduced headaches, joint pain, sweating, fatigue, and numbness.[3]
Safety and Symptom Improvements
The drug proved generally well-tolerated, with no serious adverse events in the randomized portions of the trials. Common side effects included diarrhea, abdominal pain, nausea, and abdominal discomfort. Patient-reported outcomes via the Acromegaly Symptom Diary highlighted meaningful reductions in disease burden.[1]
- Headaches
- Joint pain
- Sweating
- Fatigue
- Swelling or numbness/tingling
These gains address gaps in prior therapies, where up to 77 percent of patients experienced injection reactions and over half noted symptom flares during off periods.
Launch Plans and Broader Horizons
Crinetics plans initial commercialization in Germany and Austria, leveraging the orphan designation for market exclusivity benefits. The U.S. launch of Palsonify, approved by the FDA in September 2025, has shown strong early uptake as the first oral option there. Partnerships extend its reach: Sanwa Kagaku Kenkyusho submitted a new drug application in Japan, and Crinetics filed in Brazil last month.[1][4]
Paltusotine also advances in carcinoid syndrome trials, signaling Crinetics’ expanding endocrinology pipeline. This EU nod not only validates the therapy’s profile but also promises broader access for a condition long underserved by convenient treatments.
As Palsonify rolls out across Europe, it could redefine management standards, offering patients reliable control without needles. For the estimated 15,000 to 20,000 Europeans living with acromegaly, this development arrives at a critical juncture in therapeutic innovation.[1]